ADMA Adma Biologics Inc
Price (delayed)
$19.42
Market cap
$4.61B
P/E Ratio
22.85
Dividend/share
N/A
EPS
$0.85
Enterprise value
$4.58B
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at
Highlights
The EPS has surged by 193% since the previous quarter
The company's net income has surged by 190% QoQ
ADMA's quick ratio has soared by 75% YoY but it is down by 10% QoQ
Key stats
What are the main financial stats of ADMA
Market
Valuations
Earnings
Shares outstanding
237.62M
Market cap
$4.61B
Enterprise value
$4.58B
Price to earnings (P/E)
22.85
Price to book (P/B)
13.15
Price to sales (P/S)
10.61
EV/EBIT
32.83
EV/EBITDA
31.04
EV/Sales
10.75
Revenue
$426.45M
Gross profit
$219.55M
Operating income
$138.98M
Net income
$197.67M
EBIT
$139.64M
EBITDA
$147.69M
Free cash flow
$110.45M
Per share
Balance sheet
Liquidity
EPS
$0.85
EPS diluted
$0.81
Free cash flow per share
$0.47
Book value per share
$1.48
Revenue per share
$1.83
TBVPS
$2.08
Total assets
$488.68M
Total liabilities
$139.66M
Debt
$73.56M
Equity
$349.02M
Working capital
$275.87M
Debt to equity
0.21
Current ratio
5.97
Quick ratio
2.76
Net debt/EBITDA
-0.2
Margins
Efficiency
Dividend
EBITDA margin
34.6%
Gross margin
51.5%
Net margin
46.4%
Operating margin
32.6%
Return on assets
49.2%
Return on equity
85.7%
Return on invested capital
37%
Return on capital employed
32.2%
Return on sales
32.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADMA stock price
How has the Adma Biologics stock price performed over time
Intraday
-2.12%
1 week
-3.96%
1 month
18.49%
1 year
196.94%
YTD
13.24%
QTD
-2.12%
Financial performance
How have Adma Biologics's revenue and profit performed over time
Revenue
$426.45M
Gross profit
$219.55M
Operating income
$138.98M
Net income
$197.67M
Gross margin
51.5%
Net margin
46.4%
The company's net income has surged by 190% QoQ
The company's net margin has surged by 161% QoQ
The gross profit has soared by 147% YoY and by 17% from the previous quarter
ADMA's revenue has surged by 65% year-on-year and by 11% since the previous quarter
Growth
What is Adma Biologics's growth rate over time
Valuation
What is Adma Biologics stock price valuation
P/E
22.85
P/B
13.15
P/S
10.61
EV/EBIT
32.83
EV/EBITDA
31.04
EV/Sales
10.75
The EPS has surged by 193% since the previous quarter
The equity has surged by 158% year-on-year and by 51% since the previous quarter
The price to book (P/B) is 132% higher than the 5-year quarterly average of 5.8 but 2.6% lower than the last 4 quarters average of 13.8
ADMA's price to sales (P/S) is 117% higher than its 5-year quarterly average of 5.0 and 25% higher than its last 4 quarters average of 8.7
ADMA's revenue has surged by 65% year-on-year and by 11% since the previous quarter
Efficiency
How efficient is Adma Biologics business performance
The company's return on assets has surged by 162% QoQ
ADMA's ROE has soared by 123% QoQ
The company's return on invested capital rose by 50% QoQ
The return on sales has grown by 38% since the previous quarter
Dividends
What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADMA.
Financial health
How did Adma Biologics financials performed over time
ADMA's quick ratio has soared by 75% YoY but it is down by 10% QoQ
Adma Biologics's total assets has increased by 48% YoY and by 25% from the previous quarter
The company's debt is 79% lower than its equity
The equity has surged by 158% year-on-year and by 51% since the previous quarter
Adma Biologics's debt to equity has shrunk by 78% YoY and by 52% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.